5K6F

Crystal structure of prefusion-stabilized RSV F single-chain 9-19 DS-Cav1 variant.


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.59 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.203 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.

Joyce, M.G.Zhang, B.Ou, L.Chen, M.Chuang, G.Y.Druz, A.Kong, W.P.Lai, Y.T.Rundlet, E.J.Tsybovsky, Y.Yang, Y.Georgiev, I.S.Guttman, M.Lees, C.R.Pancera, M.Sastry, M.Soto, C.Stewart-Jones, G.B.Thomas, P.V.Van Galen, J.G.Baxa, U.Lee, K.K.Mascola, J.R.Graham, B.S.Kwong, P.D.

(2016) Nat.Struct.Mol.Biol. 23: 811-820

  • DOI: 10.1038/nsmb.3267
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Structure-based design of vaccines, particularly the iterative optimization used so successfully in the structure-based design of drugs, has been a long-sought goal. We previously developed a first-generation vaccine antigen called DS-Cav1, comprisin ...

    Structure-based design of vaccines, particularly the iterative optimization used so successfully in the structure-based design of drugs, has been a long-sought goal. We previously developed a first-generation vaccine antigen called DS-Cav1, comprising a prefusion-stabilized form of the fusion (F) glycoprotein, which elicits high-titer protective responses against respiratory syncytial virus (RSV) in mice and macaques. Here we report the improvement of DS-Cav1 through iterative cycles of structure-based design that significantly increased the titer of RSV-protective responses. The resultant second-generation 'DS2'-stabilized immunogens have their F subunits genetically linked, their fusion peptides deleted and their interprotomer movements stabilized by an additional disulfide bond. These DS2 immunogens are promising vaccine candidates with superior attributes, such as their lack of a requirement for furin cleavage and their increased antigenic stability against heat inactivation. The iterative structure-based improvement described here may have utility in the optimization of other vaccine antigens.


    Organizational Affiliation

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Fusion glycoprotein F0
F
450Human respiratory syncytial virus A (strain A2)Mutation(s): 8 
Gene Names: F
Find proteins for P03420 (Human respiratory syncytial virus A (strain A2))
Go to UniProtKB:  P03420
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.59 Å
  • R-Value Free: 0.237 
  • R-Value Work: 0.203 
  • Space Group: P 41 3 2
Unit Cell:
Length (Å)Angle (°)
a = 168.934α = 90.00
b = 168.934β = 90.00
c = 168.934γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
PHASERphasing
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2016-08-10
    Type: Initial release
  • Version 1.1: 2016-09-21
    Type: Database references